TB-500 + BPC-157 (Wolverine Blend): What They Are, What the Research Shows, and How to Verify Purity

The Wolverine blend is a single vial of two synthetic peptides freeze-dried together: TB-500 (Ac-LKKTETQ, a 7-amino-acid fragment of thymosin beta-4) and BPC-157 (a 15-amino-acid peptide). Neither compound has completed human trials, the combination itself has essentially no published research, and neither is approved as a drug in any country.

What is the TB-500 + BPC-157 blend?

It is a single vial containing two different synthetic peptides that were freeze-dried together, a process called co-lyophilisation. Neither compound is a drug approved by any regulator. The blend is not a formulation that has been through any approval process; it is two research chemicals combined in one container, and different suppliers use different ratios.

The two components come from completely separate research literatures:

• BPC-157 – a 15-amino-acid peptide based on a sequence found in human gastric juice. Its research base is large, almost entirely animal and cell work, and is covered in depth in our BPC-157 research overview.
• TB-500 – a short synthetic fragment of a much larger natural protein called thymosin beta-4. This is the component most people misunderstand, so it gets the bulk of this article.

One point worth stating immediately, because it is the single most important fact on this page: there is no published, peer-reviewed research on the two compounds given together. Studies exist on each molecule separately, in animals and in cell culture. The combination itself has not been characterised in the literature. Any confident description of what the blend “does” is an extrapolation, not a finding.

TB-500 is not thymosin beta-4 (and the difference matters)

Vendor pages routinely use “TB-500” and “thymosin beta-4” as if they were the same thing. They are not, and conflating them makes the evidence base look far stronger than it is.

Thymosin beta-4 (often written Tβ4) is a naturally occurring protein found in most human cells. It is 43 amino acids long and its main known job is binding actin – the structural protein cells use to build their internal scaffolding and to move. Tβ4 is what almost all of the well-known research was actually done on.

TB-500 is a much smaller synthetic piece of that protein. When analytical chemists put commercial TB-500 through high-resolution mass spectrometry, what they identified was the N-terminally acetylated fragment covering residues 17 to 23 of thymosin beta-4 – a chain of just seven amino acids, written Ac-LKKTETQ (Esposito et al., 2012, Drug Testing and Analysis, PMID 22962027). That region is known as the actin-binding domain, which is why it was chosen.

So the practical relationship is: TB-500 is roughly one sixth of the length of the protein most of the research studied. A finding about the 43-amino-acid protein is not automatically a finding about the 7-amino-acid fragment. Some studies have tested the short fragment directly – and those are the ones flagged below – but they are a minority of the literature that gets cited under the “TB-500” name.

A deliberate omission: this page does not print a CAS number for TB-500. The values quoted by suppliers differ depending on whether the material is the acetylated or the free peptide, and on the salt form, and those choices change both the registry number and the molar mass. The number that matters is the one on the certificate for the specific batch in hand, cross-checked against the mass-spectrometry result on the same document.

What the research has actually examined

Below are representative papers, with their models and their limits. Every one of them is an animal or laboratory study. Read the “Model” line before the finding – in this literature, the model is most of the story.

And the combination? A literature search for the two compounds studied together returns nothing usable – no controlled animal study, no cell study, no pharmacology characterising them as a pair. The blend exists because both molecules appear in overlapping tissue-repair research literatures, not because a study established that combining them does anything a single compound does not. That is a gap in the evidence, and it should be described as one.

How researchers think TB-500 works

The mechanism described in the literature starts with actin. Actin is the protein cells use to build their internal skeleton and to crawl from place to place. Thymosin beta-4’s best-established job is sequestering actin – holding individual actin units in reserve so a cell can rapidly assemble or dismantle its scaffolding. Cell migration depends on exactly that machinery, which is why so many of the studies above measured cells moving.

A 2010 review in FASEB Journal examined which parts of the thymosin beta-4 molecule are responsible for which measured activities, and identified short internal sequences – including the actin-binding region – as the active sites in several of the assays (Sosne et al., 2010, PMID 20179146). That work is the reason a 7-amino-acid fragment is sold at all: it is an attempt to isolate the active region of a much larger protein.

BPC-157’s most-discussed proposed mechanism is different again – angiogenesis, the formation of new blood vessels, associated in animal studies with VEGF signalling. Two different proposed mechanisms studied in two separate literatures is not, by itself, evidence that they combine usefully.

All of the above is mechanism observed in models. It explains why researchers study these compounds. It does not establish what either one does in a human being.

What is known about safety

Honestly: much less than the volume of online discussion implies.

• No human safety data for TB-500. There are no completed, published, controlled human trials of the acetylated 7-amino-acid fragment. No human safety profile exists for it.
• The human trials people cite are of a different molecule. Full-length thymosin beta-4 has genuinely been through human trials as an investigational topical drug candidate – for example a randomized Phase 3 study of an ophthalmic solution in an eye-surface disorder (Sosne et al., 2022, PMID 36613994), and an earlier European randomized study in venous ulcers (Guarnera et al., 2007, PMID 17495250). Those studies used the full 43-amino-acid protein, applied topically, as an unapproved investigational medicine. They are not evidence about a 7-amino-acid fragment in a research vial, and they did not result in an approved drug.
• No human safety data for BPC-157 either, and the U.S. FDA has stated that compounded products containing BPC-157 may cause immune-system reactions and that the available data are insufficient to evaluate its safety in people.
• TB-500 is a flagged doping agent. It is prohibited in sport, and anti-doping laboratories have published dedicated detection methods for it – including in equine testing (Ho et al., 2012, PMID 23084823). That is a factual regulatory position worth knowing.
• Blends add an unknown. Even if each compound had a characterised safety profile, a combination would not automatically inherit it. Nothing published examines the two together.

PeptSelect does not publish preparation or usage guidance for this blend, or for any peptide. Not as a legal formality – for unapproved compounds with no human safety data, there is no such guidance that could responsibly be given.

Why a two-peptide vial is harder to verify

This is the part that is genuinely actionable, and it is where a blend differs from a single compound. A vial containing two peptides has to answer more questions than a vial containing one:

• Are both compounds actually present? A blend can be short on one component and still look like a full vial.
• In what ratio? “10 mg” describes the total. It does not say how that total splits between the two peptides. The split should be stated, not assumed.
• Is each one pure? A purity figure for a blend is meaningless unless it is clear what was measured. Two peptides produce two main peaks on a chromatogram, and each needs its own identification.
• Does the mass spectrometry confirm both identities? Two distinct molecular weights should be confirmed – roughly 889 for the acetylated TB-500 fragment and roughly 1419.5 for BPC-157 free acid, adjusted for the actual salt form.

A single unlabelled “99%” with no chromatogram behind it does not answer any of those questions. If you have not read a chromatogram before, our guides to reading HPLC purity and what HPLC actually is cover how to interpret one, and mass spectrometry explains how identity is confirmed by mass.

How to verify what you actually received

Whatever the research eventually shows about these molecules, the one thing fully within a buyer’s control today is confirming that the vial contains what the label claims. In the research-peptide market that is where most of the real-world risk sits: mislabelled, under-filled, or impure material.

On a batch certificate for a two-peptide blend, the things worth checking are:

• Both identities – mass spectrometry confirming two molecular weights matching the two declared peptides and their salt forms.
• A real chromatogram – an actual HPLC trace, not just an asserted percentage, with the peaks attributable to the declared components.
• The stated split – how the total milligrams divide between the two peptides, and whether the figure is net peptide content or gross powder weight.
• Batch matching – the lot number on the certificate matching the batch number on your order confirmation. Our guide to batch and lot verification covers the workflow.
• A named independent lab – a real testing house identified by name, not an anonymous “tested” stamp. Why that matters is set out in why third-party testing matters.

Every PeptSelect batch is matched to a published third-party certificate in the COA Vault, and the full testing process is documented in How we test.